Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639714 · ClinicalTrials.gov registry record · Phase 1
A Study of a Personalized Neoantigen Cancer Vaccine
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Gritstone bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 11
- Study locations
NCT03639714: Completed Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Gritstone bio.
NCT03639714 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that has completed, run by Gritstone bio. The registered enrollment target is 29 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03639714, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, has completed, sponsored by Gritstone bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.
Conditions Studied
Interventions
- BIOLOGICAL nivolumab
- BIOLOGICAL ipilimumab
- BIOLOGICAL GRT-C901
- BIOLOGICAL GRT-R902
Study Locations (11)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Columbia University Medical Center - New York
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic - Jacksonville
Illinois
- The University of Chicago - Chicago
Minnesota
- Mayo Clinic - Rochester
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Tennessee
- Tennessee Oncology - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 1 |
What the finished NCT03639714 record still lists
NCT03639714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which nivolumab is the first listed.
NCT03639714 lists 11 locations in 10 states (New York, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT03639714 about?
NCT03639714 is a clinical study titled "A Study of a Personalized Neoantigen Cancer Vaccine". The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colore...
What is the current status of trial NCT03639714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2019-02-13. Estimated completion is 2022-11-10.
What conditions does trial NCT03639714 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Carcinoma, Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT03639714?
The interventions under investigation include: nivolumab (BIOLOGICAL), ipilimumab (BIOLOGICAL), GRT-C901 (BIOLOGICAL), GRT-R902 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03639714?
This trial is sponsored by Gritstone bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03639714 being conducted?
This trial has 11 study locations across Arizona, Florida, Illinois, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03639714's enrollment target sits among peer trials
29 398th of 454 higher than 56 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI